Literature DB >> 17320140

Anti HIV-1 virucidal activity of polyamide nucleic acid-membrane transducing peptide conjugates targeted to primer binding site of HIV-1 genome.

Snehlata Tripathi1, Binay Chaubey, Beverly E Barton, Virendra N Pandey.   

Abstract

We have shown that polyamide nucleic acids (PNAs) targeted to the PBS (PNA(PBS)) and A-loop (PNA(A-loop)) sequences, when transfected into cells, inhibit HIV-1 replication by blocking the initiation of reverse transcription via destabilizing tRNA(3)(Lys) primer from the viral genome. Here we demonstrate that both PNA(PBS) and PNA(A-loop) conjugated with the membrane-transducing peptide (MTD) vectors penetratin and Tat are rapidly taken up by cells and inhibit HIV-1 replication. Moreover, MTD peptide conjugates of PNA(PBS) and PNA(A-loop) displayed potent virucidal activity against HIV-1. Brief exposure of HIV-1 virions to these conjugates rendered them noninfectious. The IC(50) values for virucidal activity were in the range of approximately 50 nM; IC(50) values for inhibition of HIV-1 replication/infection were 0.5 microM-0.7 microM. The virucidal property of these conjugates suggests that a cocktail of anti-HIV-1 PNA-MTD peptide conjugates targeting critical regions of the HIV-1 genome could serve as a prophylactic agent for inactivating HIV-1 virions after exposure to HIV-1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17320140      PMCID: PMC2038983          DOI: 10.1016/j.virol.2007.01.016

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  43 in total

1.  Public health. AIDS vaccine trial produces disappointment and confusion.

Authors:  Jon Cohen
Journal:  Science       Date:  2003-02-28       Impact factor: 47.728

2.  Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake.

Authors:  Jean Philippe Richard; Kamran Melikov; Eric Vives; Corinne Ramos; Birgit Verbeure; Mike J Gait; Leonid V Chernomordik; Bernard Lebleu
Journal:  J Biol Chem       Date:  2002-10-30       Impact factor: 5.157

3.  Direct and rapid cytosolic delivery using cell-penetrating peptides mediated by pyrenebutyrate.

Authors:  Toshihide Takeuchi; Michie Kosuge; Akiko Tadokoro; Yukio Sugiura; Mayumi Nishi; Mitsuhiro Kawata; Naomi Sakai; Stefan Matile; Shiroh Futaki
Journal:  ACS Chem Biol       Date:  2006-06-20       Impact factor: 5.100

4.  Destabilization of tRNA3(Lys) from the primer-binding site of HIV-1 genome by anti-A loop polyamide nucleotide analog.

Authors:  N Kaushik; T T Talele; R Monel; P Palumbo; V N Pandey
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

5.  Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production.

Authors:  Neerja Kaushik; Amartya Basu; Paul Palumbo; Rene L Myers; Virendra N Pandey
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.

Authors:  K A Nagashima; D A Thompson; S I Rosenfield; P J Maddon; T Dragic; W C Olson
Journal:  J Infect Dis       Date:  2001-03-08       Impact factor: 5.226

7.  Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.

Authors:  Lut Van Damme; Gita Ramjee; Michel Alary; Bea Vuylsteke; Verapol Chandeying; Helen Rees; Pachara Sirivongrangson; Léonard Mukenge-Tshibaka; Virginie Ettiègne-Traoré; Charn Uaheowitchai; Salim S Abdool Karim; Benoît Mâsse; Jos Perriëns; Marie Laga
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

8.  Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment.

Authors:  J Bestman-Smith; J Piret; A Désormeaux; M J Tremblay; R F Omar; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

9.  Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

Authors:  Jeffrey M Jacobson; Robert J Israel; Israel Lowy; Nancy A Ostrow; Linda S Vassilatos; Melanie Barish; Diep N H Tran; Brian M Sullivan; Thomas J Ketas; Tobias J O'Neill; Kirsten A Nagashima; Wei Huang; Christos J Petropoulos; John P Moore; Paul J Maddon; William C Olson
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  Targeting the single-strand G-rich overhang of telomeres with PNA inhibits cell growth and induces apoptosis of human immortal cells.

Authors:  Masood A Shammas; Xiaohai Liu; Gérald Gavory; Kevin D Raney; Shankar Balasubramanian; Robert J Shmookler Reis
Journal:  Exp Cell Res       Date:  2004-04-15       Impact factor: 3.905

View more
  13 in total

1.  A peptide nucleic acid-aminosugar conjugate targeting transactivation response element of HIV-1 RNA genome shows a high bioavailability in human cells and strongly inhibits tat-mediated transactivation of HIV-1 transcription.

Authors:  Indrajit Das; Jérôme Désiré; Dinesh Manvar; Isabelle Baussanne; Virendra N Pandey; Jean-Luc Décout
Journal:  J Med Chem       Date:  2012-06-22       Impact factor: 7.446

2.  Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase.

Authors:  Jeffrey J DeStefano; Gauri R Nair
Journal:  Oligonucleotides       Date:  2008-06

3.  Immunological response to peptide nucleic acid and its peptide conjugate targeted to transactivation response (TAR) region of HIV-1 RNA genome.

Authors:  Alok Upadhyay; Nicholas M Ponzio; Virendra N Pandey
Journal:  Oligonucleotides       Date:  2008-12

4.  An efficient biodelivery system for antisense polyamide nucleic acid (PNA).

Authors:  Mohamed Mehiri; Gregory Upert; Snehlata Tripathi; Audrey Di Giorgio; Roger Condom; Virendra N Pandey; Nadia Patino
Journal:  Oligonucleotides       Date:  2008-09

Review 5.  Prospects for antisense peptide nucleic acid (PNA) therapies for HIV.

Authors:  Virendra N Pandey; Alok Upadhyay; Binay Chaubey
Journal:  Expert Opin Biol Ther       Date:  2009-08       Impact factor: 4.388

6.  Pharmacokinetic analysis of polyamide nucleic-acid-cell penetrating peptide conjugates targeted against HIV-1 transactivation response element.

Authors:  Sabyasachi Ganguly; Binay Chaubey; Snehlata Tripathi; Alok Upadhyay; Prasad V S V Neti; Roger W Howell; Virendra Nath Pandey
Journal:  Oligonucleotides       Date:  2008-09

7.  Initiation of HIV Reverse Transcription.

Authors:  Catherine Isel; Chantal Ehresmann; Roland Marquet
Journal:  Viruses       Date:  2010-01-18       Impact factor: 5.818

8.  Creation of a novel peptide with enhanced nuclear localization in prostate and pancreatic cancer cell lines.

Authors:  H Dan Lewis; Ali Husain; Robert J Donnelly; Dimitrios Barlos; Sheraz Riaz; Kalyani Ginjupalli; Adetola Shodeinde; Beverly E Barton
Journal:  BMC Biotechnol       Date:  2010-10-28       Impact factor: 2.563

9.  Cell penetrating peptides in the delivery of biopharmaceuticals.

Authors:  Were Ll Munyendo; Huixia Lv; Habiba Benza-Ingoula; Lilechi D Baraza; Jianping Zhou
Journal:  Biomolecules       Date:  2012-03-30

Review 10.  Cell-Penetrating Peptides for Antiviral Drug Development.

Authors:  Melaine Delcroix; Lee W Riley
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.